General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-12 | 2024-09 | -0.46 | N/A | N/A | N/A |
2024-08-13 | 2024-06 | -0.39 | -0.59 | -0.2 | -51.28% |
2024-05-14 | 2024-03 | -0.51 | -0.68 | -0.17 | -33.33% |
2024-05-14 | 2024-03 | -0.51 | N/A | N/A | N/A |
2024-04-04 | 2023-12 | -0.89 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | -1.14 | -1.14 | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-05-22 | CLAIBORNE CARY J | Chief Executive Officer | 1.52M | Stock Award(Grant) |
2018-07-30 | GILLILAND ROBERTSON H. | Director | 0.00 | Purchase |
2018-07-30 | GOODMAN TONY | Director | 8.76K | Purchase |
2021-10-03 | JOHNSON BANKOLE A | Officer | 0.00 | Sale |
2021-12-29 | NEWMAN JAMES W. JR. | Director | 0.00 | Purchase |
2023-09-28 | SCHUYLER KEVIN | Director | 6.59K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Manchester Capital Management, LLC | 48.10K | 10.01K | 3.95% |
2023-06-29 | Vanguard Group Inc | 8.13K | 1.69K | 0.67% |
2023-06-29 | Blackrock Inc. | 7.77K | 1.62K | 0.64% |
2023-06-29 | Susquehanna International Group, LLP | 7.21K | 1.50K | 0.59% |
2023-06-29 | Geode Capital Management, LLC | 5.50K | 1.14K | 0.45% |
2023-06-29 | Renaissance Technologies, LLC | 4.28K | 891.00 | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 8.13K | 1.69K | 0.67% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.92K | 766.00 | 0.24% |
2023-05-30 | Fidelity Series Total Market Index Fund | 957.00 | 251.00 | 0.08% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 662.00 | 174.00 | 0.05% |
2023-05-30 | Fidelity Total Market Index Fund | 511.00 | 134.00 | 0.04% |
Split | Date |
---|---|
1 : 25 | 2023-08-07 |
Search Results
Featured snippet from the web
Adial Pharmaceuticals Inc (NASDAQ:ADIL)
The 1 analysts offering 12-month price forecasts for Adial Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +309.84% increase from the last price of 1.22.
Imagine how many counties and people will buy this test! Billions
Don’t worry tomorrow this will be at least 6
AM 7٪ up already
JUST HEARD BIG HUGE NEWS COMMING SOON
Why the action today
Do they report earnings today
please check Wonderful Real time scanner app With free news : Android: https://dwz1.cc/zkNVfOg
iOS: https://dwz1.cc/KuVxe7Z
The Best Stock Screener App Review So Far:
https://dwz1.cc/CjfRfWk